KR102146848B1 - 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법 - Google Patents

3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법 Download PDF

Info

Publication number
KR102146848B1
KR102146848B1 KR1020157006019A KR20157006019A KR102146848B1 KR 102146848 B1 KR102146848 B1 KR 102146848B1 KR 1020157006019 A KR1020157006019 A KR 1020157006019A KR 20157006019 A KR20157006019 A KR 20157006019A KR 102146848 B1 KR102146848 B1 KR 102146848B1
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
compound
lymphoma
cancer
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157006019A
Other languages
English (en)
Korean (ko)
Other versions
KR20150039850A (ko
Inventor
피터 에이취. 샤퍼
아니타 간디
Original Assignee
셀진 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 셀진 코포레이션 filed Critical 셀진 코포레이션
Priority to KR1020207023283A priority Critical patent/KR102266510B1/ko
Publication of KR20150039850A publication Critical patent/KR20150039850A/ko
Application granted granted Critical
Publication of KR102146848B1 publication Critical patent/KR102146848B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020157006019A 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법 Active KR102146848B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020207023283A KR102266510B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261681447P 2012-08-09 2012-08-09
US61/681,447 2012-08-09
US201261722727P 2012-11-05 2012-11-05
US61/722,727 2012-11-05
PCT/US2013/054055 WO2014025960A1 (en) 2012-08-09 2013-08-08 Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207023283A Division KR102266510B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법

Publications (2)

Publication Number Publication Date
KR20150039850A KR20150039850A (ko) 2015-04-13
KR102146848B1 true KR102146848B1 (ko) 2020-08-21

Family

ID=49004013

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020157006019A Active KR102146848B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
KR1020217018115A Active KR102414005B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
KR1020207023283A Active KR102266510B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217018115A Active KR102414005B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
KR1020207023283A Active KR102266510B1 (ko) 2012-08-09 2013-08-08 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법

Country Status (31)

Country Link
US (4) US20140045843A1 (https=)
EP (2) EP2882442B1 (https=)
JP (2) JP6347782B2 (https=)
KR (3) KR102146848B1 (https=)
CN (4) CN114366746A (https=)
AU (1) AU2013299627C1 (https=)
BR (1) BR112015002285B1 (https=)
CA (1) CA2881116C (https=)
CY (1) CY1124622T1 (https=)
DK (1) DK2882442T3 (https=)
EA (1) EA029485B1 (https=)
ES (1) ES2881220T3 (https=)
HR (1) HRP20211243T1 (https=)
HU (1) HUE056127T2 (https=)
IL (3) IL288506B2 (https=)
IN (1) IN2015DN00886A (https=)
LT (1) LT2882442T (https=)
MX (1) MX367869B (https=)
NI (1) NI201500012A (https=)
NZ (1) NZ628078A (https=)
PH (1) PH12015500212A1 (https=)
PL (1) PL2882442T3 (https=)
PT (1) PT2882442T (https=)
RS (1) RS62201B1 (https=)
SG (3) SG10201701057SA (https=)
SI (1) SI2882442T1 (https=)
SM (1) SMT202100457T1 (https=)
TW (2) TWI653977B (https=)
UA (1) UA116544C2 (https=)
WO (1) WO2014025960A1 (https=)
ZA (1) ZA201500564B (https=)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
US8491927B2 (en) * 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
EP2536706B1 (en) 2010-02-11 2017-06-14 Celgene Corporation Arylmethoxy isoindoline derivatives and compositions comprising and methods of using the same
ES2608967T3 (es) 2011-03-28 2017-04-17 Mei Pharma, Inc. (Aralquilamino sustituido en alfa y heteroarilalquilamino)pirimidinil y 1,3,5-triazinil benzimidazoles, composiciones farmacéuticas que los contienen, y estos compuestos para usar en el tratamiento de enfermedades proliferativas
ES2872967T3 (es) 2012-06-29 2021-11-03 Celgene Corp Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS)
US9587281B2 (en) 2012-08-14 2017-03-07 Celgene Corporation Cereblon isoforms and their use as biomarkers for therapeutic treatment
MX2015003114A (es) 2012-09-10 2015-07-06 Celgene Corp Metodos para el tratamiento de cancer de mama localmente avanzado.
US9695145B2 (en) 2013-01-22 2017-07-04 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4- morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
IL278381B2 (en) 2013-12-06 2024-08-01 Celgene Corp Methods for determining the effectiveness of a drug for the treatment of diffuse large B-cell lymphoma, multiple myeloma, and myeloid cancer
WO2015200795A1 (en) 2014-06-27 2015-12-30 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
JP2017538104A (ja) * 2014-10-07 2017-12-21 セルジーン コーポレイション 癌治療に対する臨床的感応性を予測するためのバイオマーカーの使用
CA2999179A1 (en) * 2015-09-25 2017-03-30 Celgene Corporation Methods for treating diffuse large b-cell lymphoma and the use of biomarkers as a predictor of responsiveness to drugs
WO2017117118A1 (en) 2015-12-28 2017-07-06 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases
KR102002581B1 (ko) * 2016-10-04 2019-07-22 주식회사 종근당 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물
US20180238886A1 (en) * 2017-01-31 2018-08-23 Celgene Corporation Methods for treating hematological cancer and the use of biomarkers as a predictor for responsiveness to treatment compounds
AU2018269982B2 (en) * 2017-05-16 2024-06-13 Biomed Valley Discoveries, Inc. Compositions and methods for treating cancer with atypical BRAF mutations
US11304953B2 (en) 2017-05-23 2022-04-19 Mei Pharma, Inc. Combination therapy
EP4201399A3 (en) * 2017-06-30 2023-08-09 Celgene Corporation Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl) -2,2-difluoroacetamide
TWI791552B (zh) * 2017-07-10 2023-02-11 美商西建公司 抗增生化合物及其使用方法
KR20200041358A (ko) 2017-08-14 2020-04-21 메이 파마, 아이엔씨. 병용 요법
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
US11709164B2 (en) 2017-10-26 2023-07-25 National University Of Singapore Approach for universal monitoring of minimal residual disease in acute myeloid leukemia
IL315310A (en) 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019321526A1 (en) * 2018-08-14 2021-03-25 Mei Pharma, Inc. Treatment of relapsed follicular lymphoma
EP3848371A4 (en) * 2018-09-07 2022-06-08 Medshine Discovery Inc. TRICYCLIC FURAN-SUBSTITUTED PIPERIDONEE COMPOUND
AU2019351811B2 (en) * 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
WO2020097403A1 (en) * 2018-11-08 2020-05-14 Juno Therapeutics, Inc. Methods and combinations for treatment and t cell modulation
JP7623943B2 (ja) 2018-11-30 2025-01-29 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびそれらの使用
TWI875749B (zh) 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
AR119715A1 (es) * 2019-04-12 2022-01-05 Celgene Corp Métodos para tratar linfoma no hodgkin con el uso de 2-(2,6-dioxopiperidin-3-il)-4-((2-fluoro-4-((3-morfolinoazetidin-1-il)metil)bencil)amino)isoindolin-1,3-diona
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
WO2020251972A1 (en) 2019-06-10 2020-12-17 Kymera Therapeutics, Inc. Smarca degraders and uses thereof
BR112021026517A2 (pt) 2019-06-28 2022-05-10 Kymera Therapeutics Inc Degradadores de irak e usos dos mesmos
WO2021011868A1 (en) 2019-07-17 2021-01-21 Kymera Therapeutics, Inc. Irak degraders and uses thereof
CA3154908A1 (en) * 2019-10-21 2021-04-29 Sreenivas S. Bhat Pharmaceutical compositions comprising (s)-2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dione and methods of using the sam
IL292667B1 (en) 2019-11-07 2026-02-01 Juno Therapeutics Inc Combination of T-cell therapy and (s)-3-[4-(4-morpholin-4-ylmethyl-benzyloxy)-l-oxo-3,l-dihydro-isoindol-2-yl]-piperidine-6,2-dione
JP2023505150A (ja) * 2019-12-02 2023-02-08 セルジーン コーポレーション がんの処置のための治療法
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021127190A1 (en) 2019-12-17 2021-06-24 Kymera Therapeutics, Inc. Irak degraders and uses thereof
BR112022012410A2 (pt) 2019-12-23 2022-08-30 Kymera Therapeutics Inc Degradadores smarca e usos dos mesmos
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
TW202210483A (zh) 2020-06-03 2022-03-16 美商凱麥拉醫療公司 Irak降解劑之結晶型
CN115916191A (zh) * 2020-06-25 2023-04-04 新基公司 用组合疗法治疗癌症的方法
WO2022066835A1 (en) 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
EP4259144A4 (en) 2020-12-09 2025-08-20 Kymera Therapeutics Inc SMARCA DEGRADING AGENTS AND THEIR USES
PH12023500015A1 (en) 2020-12-30 2024-03-11 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2022174268A1 (en) 2021-02-15 2022-08-18 Kymera Therapeutics, Inc. Irak4 degraders and uses thereof
AU2022271290A1 (en) 2021-05-07 2023-11-23 Kymera Therapeutics, Inc. Cdk2 degraders and uses thereof
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
EP4472967A4 (en) 2022-01-31 2026-04-15 Kymera Therapeutics Inc Iraqi Degradation Agents and Their Uses
WO2024015618A2 (en) * 2022-07-15 2024-01-18 St. Jude Children's Research Hospital, Inc. Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2025076472A1 (en) 2023-10-06 2025-04-10 Juno Therapeutics, Inc. Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
TW202532072A (zh) 2023-12-08 2025-08-16 美商西建公司 治療多發性骨髓瘤之療法
WO2025195464A1 (zh) * 2024-03-21 2025-09-25 上海惠康济民生物医药技术有限公司 取代的异吲哚啉类化合物、制备方法、药物组合物及应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196150A1 (en) * 2010-02-11 2011-08-11 Hon-Wah Man Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
CA2418835A1 (en) 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
DK1390535T3 (da) 2001-04-26 2010-12-06 Amgen Mountain View Inc Kombinatoriske biblioteker af monomer-domæner
US7498171B2 (en) 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
US7968569B2 (en) 2002-05-17 2011-06-28 Celgene Corporation Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
US7393862B2 (en) 2002-05-17 2008-07-01 Celgene Corporation Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias
EP1824796A4 (en) 2004-11-16 2010-02-17 Avidia Res Inst PROTEIN SKELETONS AND USES THEREOF
US20080051379A1 (en) 2004-12-01 2008-02-28 Trustees Of Boston University Compositions and Methods for the Treatment of Peripheral B-Cell Neoplasms
KR101791757B1 (ko) * 2007-03-20 2017-10-30 셀진 코포레이션 4'-ｏ-치환된 아이소인돌린 유도체 및 이를 포함하는 조성물 및 이의 사용 방법
EP2436387B1 (en) 2009-05-25 2018-07-25 Celgene Corporation Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex
TWI509247B (zh) * 2010-03-12 2015-11-21 西建公司 利用雷那度胺（ｌｅｎａｌｉｄｏｍｉｄｅ）治療非霍奇金氏淋巴瘤之方法及作為預測子之基因及蛋白質生物標記
AU2012229300B2 (en) * 2011-03-11 2017-04-20 Celgene Corporation Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196150A1 (en) * 2010-02-11 2011-08-11 Hon-Wah Man Arylmethoxy Isoindoline Derivatives and Compositions Comprising and Methods of Using the Same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Cancer Cell. 18(6): 580-589, (2010.12.14.)*
PNAS, vol. 108, (2011.01.04.)*

Also Published As

Publication number Publication date
IL237013B (en) 2020-08-31
KR102266510B1 (ko) 2021-06-16
ES2881220T3 (es) 2021-11-29
HRP20211243T1 (hr) 2021-11-12
CN108245518A (zh) 2018-07-06
KR102414005B1 (ko) 2022-06-27
TW201828944A (zh) 2018-08-16
US20190388429A1 (en) 2019-12-26
US20140045843A1 (en) 2014-02-13
JP6347782B2 (ja) 2018-06-27
CA2881116C (en) 2021-07-20
IL237013A0 (en) 2015-03-31
SMT202100457T1 (it) 2021-09-14
CN114366746A (zh) 2022-04-19
ZA201500564B (en) 2016-06-29
EA201590345A1 (ru) 2015-06-30
AU2013299627B2 (en) 2018-02-15
MX367869B (es) 2019-09-10
IN2015DN00886A (https=) 2015-06-12
IL276319A (en) 2020-09-30
BR112015002285B1 (pt) 2022-05-10
HK1211489A1 (en) 2016-05-27
AU2013299627C1 (en) 2018-05-31
EP3949968A1 (en) 2022-02-09
US20160256468A1 (en) 2016-09-08
LT2882442T (lt) 2021-09-27
CA2881116A1 (en) 2014-02-13
CN114344307A (zh) 2022-04-15
UA116544C2 (uk) 2018-04-10
MX2015001775A (es) 2015-05-12
SG10202108516PA (en) 2021-09-29
EA029485B1 (ru) 2018-04-30
IL276319B (en) 2022-01-01
KR20200098730A (ko) 2020-08-20
PH12015500212A1 (en) 2015-03-30
IL288506B1 (en) 2023-05-01
IL288506B2 (en) 2023-09-01
CN104837491A (zh) 2015-08-12
SG10201701057SA (en) 2017-03-30
KR20210073617A (ko) 2021-06-18
PT2882442T (pt) 2021-08-17
HUE056127T2 (hu) 2022-01-28
TW201434466A (zh) 2014-09-16
NZ628078A (en) 2017-01-27
PL2882442T3 (pl) 2021-12-13
AU2013299627A1 (en) 2015-02-05
JP2018100276A (ja) 2018-06-28
TWI653977B (zh) 2019-03-21
EP2882442A1 (en) 2015-06-17
SG11201500998QA (en) 2015-04-29
CN108245518B (zh) 2021-08-31
WO2014025960A1 (en) 2014-02-13
SI2882442T1 (sl) 2021-11-30
CY1124622T1 (el) 2022-07-22
US20260007679A1 (en) 2026-01-08
TWI723266B (zh) 2021-04-01
DK2882442T3 (da) 2021-08-16
BR112015002285A2 (pt) 2017-07-04
KR20150039850A (ko) 2015-04-13
NI201500012A (es) 2019-05-10
IL288506A (en) 2022-01-01
RS62201B1 (sr) 2021-08-31
JP2015524478A (ja) 2015-08-24
EP2882442B1 (en) 2021-06-09

Similar Documents

Publication Publication Date Title
KR102146848B1 (ko) 3-(4-((4-모르포리노메틸)벤질)옥시)-1-옥소이소인돌린-2-일)피페리딘-2,6-디온을 이용한 암의 치료방법
JP6348192B2 (ja) ３−（５−アミノ−２−メチル−４−オキソ−４ｈ−キナゾリン−３−イル）−ピペリジン−２，６−ジオンを用いる癌の治療方法
US20150224104A1 (en) Methods for the treatment of locally advanced breast cancer
HK40068746A (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
HK1211489B (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20150306

Patent event code: PA01051R01D

Comment text: International Patent Application

AMND Amendment
PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180802

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20191218

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20200228

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20191218

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20200228

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20200214

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150310

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20200515

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20200429

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20200228

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20200214

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150310

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200812

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200814

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200814

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20230705

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20240703

Start annual number: 5

End annual number: 5